Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Cyclophosphamide for Steroid-Refractory Acute GVHD
NCT00492921Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2007
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose of High-dose Cyclophosphamide at Day 28 and GVHD Response Rate at Day 28. Started May 2007; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00492921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492921.